Rodman David Malcom 4
4 · Mineralys Therapeutics, Inc. · Filed Mar 16, 2026
Research Summary
AI-generated summary of this filing
Mineralys (MLYS) CMO Rodman Malcom Exercises Options, Sells Shares
What Happened
- Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics (MLYS), exercised stock options to acquire 14,057 shares (exercises at $1.08, $10.20 and $14.25) and then sold a total of 20,406 shares in open‑market transactions. The reported gross proceeds from the sales were approximately $542,973. The exercises required cash payments of about $102,364 in aggregate.
- These sales were executed under a Rule 10b5‑1 trading plan (adopted Oct 6, 2025), and most shares appear to have been sold immediately or shortly after exercise (i.e., effectively a cashless conversion followed by sales).
Key Details
- Transaction dates: March 12–13, 2026; Form 4 filed March 16, 2026 (no late‑filing flag shown in the provided data).
- Exercises (acquired): 6,348 @ $1.08 (paid $6,856); 3,542 @ $10.20 (paid $36,128); 4,167 @ $14.25 (paid $59,380) — total exercised = 14,057 shares (total paid ≈ $102,364).
- Sales (disposed): 6,348 @ $27.37 (≈ $173,748); 10,726 @ $25.91 (≈ $277,922); 3,079 @ $27.37 (≈ $84,265); 253 @ $27.82 (≈ $7,038) — total sold = 20,406 shares (total proceeds ≈ $542,973).
- Weighted‑average price notes: sales reported as weighted averages across multiple transactions (ranges reported in the filing: $25.77–$26.76, $26.772–$27.720, and $27.02–$27.92). The reporting person offered to provide detailed per‑trade prices on request.
- Footnotes: F1 = trades effected under a 10b5‑1 plan; F5/F6 describe option vesting schedules (one vests 25% after year 1 then monthly; another vests monthly over 4 years).
- Shares owned after transaction: not provided in the excerpt supplied.
Context
- For retail investors: this was primarily option exercises followed by open‑market sales. When an insider exercises options and promptly sells the shares (as here), it is often a routine liquidity event rather than an explicit bullish or bearish signal. The presence of a 10b5‑1 plan means the sales were pre‑arranged, which further indicates they were planned transactions, not necessarily reactive to non‑public information.
Insider Transaction Report
Form 4
Rodman David Malcom
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-12$1.08/sh+6,348$6,856→ 88,837 total - Sale
Common Stock
[F1][F2]2026-03-12$27.37/sh−6,348$173,748→ 82,489 total - Exercise/Conversion
Common Stock
[F1]2026-03-13$10.20/sh+3,542$36,128→ 86,031 total - Exercise/Conversion
Common Stock
[F1]2026-03-13$14.25/sh+4,167$59,380→ 90,198 total - Sale
Common Stock
[F1][F3]2026-03-13$25.91/sh−10,726$277,922→ 79,472 total - Sale
Common Stock
[F1][F4]2026-03-13$27.37/sh−3,079$84,265→ 76,393 total - Sale
Common Stock
[F1]2026-03-13$27.82/sh−253$7,038→ 76,140 total - Exercise/Conversion
Stock Option
[F1][F5]2026-03-12−6,348→ 25,395 totalExercise: $1.08Exp: 2032-07-11→ Common Stock (6,348 underlying) - Exercise/Conversion
Stock Option
[F1][F6]2026-03-13−3,542→ 123,959 totalExercise: $10.20Exp: 2035-02-13→ Common Stock (3,542 underlying) - Exercise/Conversion
Stock Option
[F1][F5]2026-03-13−4,167→ 95,834 totalExercise: $14.25Exp: 2034-02-13→ Common Stock (4,167 underlying)
Footnotes (6)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.02 to $27.92. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.76. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.772 to $27.720. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- [F5]The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
- [F6]The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
Signature
/s/ Adam Levy, Attorney-in-fact|2026-03-16